Prescription For Change: Consumer Perceptions Of Weight Loss Medications
Obesity is a global epidemic, and the United States is no exception. Over the past few decades, obesity rates have surged. Between August 2021 and August 2023, two in five (40.3%) American adults had obesity, and nearly one in ten (9.4%) had severe obesity (BMI ≥ 40). In 2023, 23 states reported adult obesity rates exceeding 35%—a stark contrast to 2013, when no state had reached this threshold. More Than Meets The Eye Obesity is a complex disease with emotional, physical, and social dimensions. While the public discourse often oversimplifies weight management to “eat less, move more” and finger-pointing prevails, the reality involves genetic predispositions, co-morbidities, lifestyle factors, and medications. Obesity can also be deeply emotional and personal. Solutions must be comprehensive and tailored, reflecting the multifaceted nature of the condition. Further, the scale is not necessarily a linear destination for most consumers. As scientists have worked to crack the code on how to best support Americans in successfully achieving and sustaining weight management, Americans have continued to lose weight and “find” it again – on repeat – pointing to the need for an innovative and enduring solution. A Trip Down Memory Lane Weight loss medications have been part of medical history since the FDA approved the first one in 1947. However, next-gen obesity medications have been game-changers. The advent of GLP-1 receptor agonists in 2014, and their increased use in recent years, revolutionized obesity treatment. While their effectiveness has generated excitement, barriers such as cost and potential side effects remain. Consumer perceptions of obesity medications have also evolved. According to the annual IFIC Food & Health Survey, the percentage of Americans preferring medication to lifestyle changes increased from 16% in 2012 to 27% in 2024, reflecting growing acceptance of pharmaceutical interventions. In total, the innovation and disruption to the […]
insights